Germany's Merck KGaA anticipates significant currency headwinds will continue to suppress its earnings throughout the current year.
In its latest financial report, which also marks the final results under outgoing CEO Belen Garijo, the life-sciences and chemical conglomerate projected adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) to fall within €5.5 billion to €6 billion. This outlook is notably lower than the €6.11 billion reported for the previous year, despite a 0.6% rise in adjusted EBITDA last year.
Net sales for the upcoming year are expected to be flat at best, ranging from €20 billion to €21.1 billion, representing an organic change between a 1% fall and a 2% rise. For the prior year, net sales reached €21.1 billion, growing 3.1% organically, driven by strong performance in its life-science and healthcare divisions, which mitigated a decline in electronics.
After-tax profit for the last year decreased by 6.1% to €2.615 billion. The company is also preparing for a leadership transition, with Kai Beckmann set to take over as CEO in May.
Investors should note the persistent foreign-exchange pressures and the implications of new leadership on future strategic direction.
